Previous 10 | Next 10 |
2024-04-02 07:37:07 ET More on Annovis Bio Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects Annovis And Alzheimer's Disease: The Best-Laid Plans Stocks To Watch: Eyes On Chipmakers, Tesla, Netflix And BrightSpring IPO Annovis...
MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fo...
Further look at earlier Phase 1b study by ADCS unveils confirmatory data MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced the publi...
2024-03-20 16:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-20 12:25:51 ET More on Mid-day movers & stocks. Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript Personalis Q4 2023 Earnings Preview XTI Aircraft that will merge with Inpixon gets Chinese patent for an aircraft Seeking Alpha’s Quant...
2024-03-20 09:50:03 ET More on Annovis Bio Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects Annovis And Alzheimer's Disease: The Best-Laid Plans Stocks To Watch: Eyes On Chipmakers, Tesla, Netflix And BrightSpring IPO Annovis...
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its phase II/III study of buntanetap in patients wi...
2024-02-29 00:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’...
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients w...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
0.00%Change Percent:
Annovis Bio Inc. Company Name:
ANVS Stock Symbol:
OTCMKTS Market:
Annovis Bio Inc. Website:
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...
Annovis Bio (NYSE: ANVS) , a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new data from its phase 3 PD s...
Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a very pronounced improvement. Buntanetap showed statistical improvement in the ...